English Polski
Vol 19, No 3 (2022)
Review paper
Published online: 2021-12-27
Page views 3240
Article views/downloads 117
Get Citation

Connect on Social Media

Connect on Social Media

May application of oxytocin be relevant in the therapy of perinatal mental disorders?

Miłosz Gołyszny1, Magdalena Durańska2, Oliwia Korzonek2, Michał Zieliński1, Ewa Obuchowicz1
Psychiatria 2022;19(3):214-226.

Abstract

The perinatal period is a time, when mental diseases occur more frequently, than in other stages of life. Treatment of postpartum depression, psychosis, anxiety is a very hard task. Many psychotropic drugs display a toxic potential during the perinatal period. Hence, it seems that, searching for an alternative pharmacotherapy is relevant. Oxytocin is a substance, that may be successfully used in gynecological treatment. However, its potential is definitely greater. Studies from recent years indicated, that oxytocin is involved in complex pathomechanism of affective disorders. Latest outcomes indicate, that intranasal administration of oxytocin is effective in the treatment of anxiety- and depressive behaviors. The aim of the study is based on the question: Is oxytocin relevant for mental disorders in perinatal period therapy? This question was posed in order to gain psychiatric knowledge about perinatal period’s mental problems and indicates putative novel therapeutic solutions. The research team has performed a review of the studies, searching well-known online scientific databases, including PubMed, ScienceDirect, Scopus and MedLine. Our findings shed light on oxytocin’s significance in a potential new therapy of perinatal mental disorders. Further studies should be focused on intranasal oxytocin administration and its effectivity in the treatment of mentioned diseases, adverse effects, pharmacovigilance, pharmacokinetics and pharmacodynamics. Still, scarce data from clinical studies do not allow the implementation of oxytocin in treatment of perinatal affective disturbances, despite of rationale psychobiological and pharmacological prerequisites. Hence, it is necessary to investigate the relation: oxytocin intervention — perinatal affective disorders.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Müldner-Nieckowski L, Cyranka K, Smiatek-Mazgaj B, et al. Multiaxial changes in pregnancy: mental health--a review of the literature. Ginekol Pol. 2014; 85(10): 784–787.
  2. Koszewska IO. O depresji w ciąży i po porodzie. Wydawnictwo Lekarskie PZWL, Warszawa 2010.
  3. Su M. Baby blues and postnatal depression in low risk mothers. Hong Kong J Gynaecol Obstet Midwifery. 2000; 1: 40-46.
  4. Gewin V. Baby blues. Nature. 2005; 433(7027): 780–781.
  5. Fromm E. Modern man’s pathology of normalcy. Pathology of normalcy. Lantern Books, New York 2011.
  6. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psych. 1994; 151(10): 1409–1416.
  7. Vajda FJE, O'Brien TJ, Graham J, et al. Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand. 2013; 128(4): 228–234.
  8. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007; 356(26): 2675–2683.
  9. Marcus SM. Depression during pregnancy: rates, risks and consequences--Motherisk Update 2008. Can J Clin Pharmacol. 2009; 16(1): e15–e22.
  10. Mulder EJH, Robles de Medina PG, Huizink AC, et al. Prenatal maternal stress: effects on pregnancy and the (unborn) child. Early Hum Dev. 2002; 70(1-2): 3–14.
  11. Bosquet M, Egeland B. Associations among maternal depressive symptomatology, state of mind and parent and child behaviors: implications for attachment-based interventions. Attach Hum Dev. 2001; 3(2): 173–199.
  12. Medved S, Bajs JanoviĆ M, Štimac Z, et al. Add-on Oxytocin in the Treatment of Postpartum Acute Schizophrenia: A Case Report. J Psychiatr Pract. 2021; 27(4): 326–332.
  13. Ellenbogen M, Cardoso C, Serravalle L, et al. T142. Intranasal Oxytocin Augments the Efficacy of Psychotherapy for Major Depressive Disorder. Biological Psychiatry. 2018; 83(9): S183.
  14. Ozsoy S, Olguner Eker O, Abdulrezzak U. The Effects of Antidepressants on Neuropeptide Y in Patients with Depression and Anxiety. Pharmacopsychiatry. 2016; 49(1): 26–31.
  15. Scantamburlo G, Hansenne M, Geenen V, et al. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial. Eur Psychiatry. 2015; 30(1): 65–68.
  16. Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010; 68(7): 678–680.
  17. Misri S. Suffering in silence: the burden of perinatal depression. Can J Psychiatry. 2007; 52(8): 477–478.
  18. Dudek D, Siwek M, Zieba A, Nowak G. Postpartum depression. Prz Lek. 2002; 59(11): 919-923.
  19. Maina G, Albert U, Bogetto F, et al. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res. 1999; 89(1): 49–58.
  20. Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum period: A systematic review. J Clin Psychiatry. 2006; 67(8): 1285–1298.
  21. Reck C, Stehle E, Reinig K, et al. Maternity blues as a predictor of DSM-IV depression and anxiety disorders in the first three months postpartum. J Affect Disord. 2009; 113(1-2): 77–87.
  22. Pop VJM, Truijens SEM, Spek V, et al. A new concept of maternity blues: Is there a subgroup of women with rapid cycling mood symptoms? J Affect Disord. 2015; 177: 74–79.
  23. Rezaie-Keikhaie K, Arbabshastan ME, Rafiemanesh H, et al. Systematic Review and Meta-Analysis of the Prevalence of the Maternity Blues in the Postpartum Period. J Obstet Gynecol Neonatal Nurs. 2020; 49(2): 127–136.
  24. Seyfried LS, Marcus SM. Postpartum mood disorders. Int Rev Psychiatry. 2003; 15(3): 231–242.
  25. Reroń A, Gierat B, Huras H. Ocena częstotliwości występowania depresji poporodowej. Gin Prakt. 2004; 12(3): 32–35.
  26. Łojko D, Suwalska A, Rybakowski J. Dwubiegunowe zaburzenia nastroju i zaburzenia depresyjne w klasyfikacji DSM-5. Psychiatr Pol. 2014; 48(2): 245–260.
  27. World Health Organization. The WHO application of ICD-10 to deaths during pregnancy, childbirth and puerperium: ICD-MM. World Health Organization. 2012.
  28. Sharma V, Khan M. Identification of bipolar disorder in women with postpartum depression. Bipolar Disord. 2010; 12(3): 335–340.
  29. O'Hara MW. Postpartum depression: what we know. J Clin Psychol. 2009; 65(12): 1258–1269.
  30. Nieland M, Roger D. Symptoms in post-partum and non-post-partum samples: Implications for postnatal depression. Journal of Reproductive and Infant Psychology. 1997; 15(1): 31–42.
  31. Mauri M, Banti S, Borri C, et al. P02-387 - Depressive symptomatology in pregnancy detected with EPDS: the problem of false positive. European Psychiatry. 2010; 25: 1403.
  32. Le Strat Y, Dubertret C, Le Foll B. Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. J Affect Disord. 2011; 135(1-3): 128–138.
  33. Silva R, Jansen K, Souza L, et al. Sociodemographic risk factors of perinatal depression: a cohort study in the public health care system. Braz J Psychiatry. 2012; 34(2): 143–148.
  34. Silverman ME, Smith L, Lichtenstein P, et al. The risk factors for postpartum depression: A population-based study. Depress Anxiety. 2017; 34(2): 178–187.
  35. Mavrogiorgou P, Illes F, Juckel G. [Perinatal obsessive-compulsive disorder]. Fortschr Neurol Psychiatr. 2011; 79(9): 507–516.
  36. Spinelli MG. Postpartum psychosis: detection of risk and management. Am J Psychiatry. 2009; 166(4): 405–408.
  37. Newman L, Judd F, Olsson CA, et al. Early origins of mental disorder - risk factors in the perinatal and infant period. BMC Psychiatry. 2016; 16: 270.
  38. Bergink V, Bouvy PF, Vervoort JSP, et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry. 2012; 169(6): 609–615.
  39. Heron J, Craddock N, Jones I. Postnatal euphoria: are 'the highs' an indicator of bipolarity? Bipolar Disord. 2005; 7(2): 103–110.
  40. Sharma V, Burt VK. DSM-V: modifying the postpartum-onset specifier to include hypomania. Arch Womens Ment Health. 2011; 14(1): 67–69.
  41. Sharma V, Corpse C. Is your depressed postpartum patient bipolar? Curr Psychiatry. 2011; 10(6): 81–83.
  42. Smith S, Heron J, Haque S, et al. Measuring hypomania in the postpartum: a comparison of the Highs Scale and the Altman Mania Rating Scale. Arch Womens Ment Health. 2009; 12(5): 323–327.
  43. Stuart S, Koleva H. Psychological treatments for perinatal depression. Best Pract Res Clin Obstet Gynaecol. 2014; 28(1): 61–70.
  44. Craske M. Cognitive-behavioral therapy. Psychotherapy theories and techniques: A reader. 2014: 79–86.
  45. O'Hara MW, Stuart S, Gorman LL, et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry. 2000; 57(11): 1039–1045.
  46. Lipsitz JD, Markowitz JC. Mechanisms of change in interpersonal therapy (IPT). Clin Psychol Rev. 2013; 33(8): 1134–1147.
  47. Gebuza G, Jaworska K, Mieczkowska E, et al. The breastfeeding after natural birth and by caesarean section. Pediatr Pol. 2015; 95(5): 384–390.
  48. Krzyżanowska–Zbucka J. Okołoporodowe zaburzenia psychiczne a krzywdzenie dzieci. Dziecko Krzywdzone. Teoria, badania, praktyka. 2010; 9(3): 44–53.
  49. ESCOP Monographs, The Scientific Foundation for Herbal Medicinal Products. Exeter: ESCOP, Stuttgart, New York: Thieme, 2003.
  50. Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep. 2010; 12(2): 96–103.
  51. Yonkers KA, Blackwell KA, Glover J, et al. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014; 10: 369–392.
  52. Ornoy A, Weinstein-Fudim L, Ergaz Z. Antidepressants, Antipsychotics, and Mood Stabilizers in Pregnancy: What Do We Know and How Should We Treat Pregnant Women with Depression. Birth Defects Res. 2017; 109(12): 933–956.
  53. Rai D, Lee BK, Dalman C, et al. Antidepressants during pregnancy and autism in offspring: population based cohort study. BMJ. 2017; 358: j2811.
  54. Payne JL. Psychopharmacology in Pregnancy and Breastfeeding. Med Clin North Am. 2019; 103(4): 629–650.
  55. Kronenfeld N, Ziv Baran T, Berlin M, et al. Chronic use of psychotropic medications in breastfeeding women: Is it safe? PLoS One. 2018; 13(5): e0197196.
  56. Emmelkamp PM, Beens H. Cognitive therapy with obsessive-compulsive disorder: a comparative evaluation. Behav Res Ther. 1991; 29(3): 293–300.
  57. March J, Mulle K. Manualized cognitive-behavioral psychotherapy for obsessive-compulsive disorder in childhood: A preliminary single case study. Journal of Anxiety Disorders. 1995; 9(2): 175–184.
  58. March JS, Franklin M, Nelson A, Foa E. Cognitive-behavioral psychotherapy for pediatric obsessive-compulsive disorder. J Clin Child Adolesc Psychol. 2001; 30(1): 8-18.
  59. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017; 317(13): 1358–1367.
  60. National Collaborating Centre for Mental Health UK. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. British Psychological Society. 2006.
  61. Kumar R. Postnatal mental illness: a transcultural perspective. Soc Psychiatry Psychiatr Epidemiol. 1994; 29(6): 250–264.
  62. Godet PF, Marie-Cardine M. [Neuroleptics, schizophrenia and pregnancy. Epidemiological and teratologic study]. Encephale. 1991; 17(6): 543–547.
  63. Stanton J, Simpson A. Filicide: a review. Int J Law Psychiatry. 2002; 25(1): 1–14.
  64. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005; 66(4): 444–9; quiz 546.
  65. Huybrechts KF, Hernandez-Diaz S, Straub L, et al. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry. 2016; 73(9): 938–946.
  66. Tomson T, Battino D, Tomson T, et al. [Malformations in the offspring of pregnant women with epilepsy. Presentation of an international registry of antiepileptic drugs and pregnancy (EURAP)]. Rev Neurol. 2002; 34(5): 476–480.
  67. Shallcross R, Bromley RL, Irwin B, et al. Liverpool Manchester Neurodevelopment Group, UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011; 76(4): 383–389.
  68. Rinaman L, Sherman TG, Stricker EM. Vasopressin and oxytocin in the central nervous system. Psychopharmacology: The fourth generation of progress. 1995: 531-542.
  69. Crowley WR, Armstrong WE. Neurochemical regulation of oxytocin secretion in lactation. Endocr Rev. 1992; 13(1): 33–65.
  70. Blanks AM, Thornton S. The role of oxytocin in parturition. BJOG. 2003; 110 Suppl 20: 46–51.
  71. Evans JJ, Reid RA, Wakeman SA, et al. Evidence that oxytocin is a physiological component of LH regulation in non-pregnant women. Hum Reprod. 2003; 18(7): 1428–1431.
  72. Lui C, Cui Xg, Wang Yx, et al. Association between neuropeptide oxytocin and male infertility. J Assist Reprod Genet. 2010; 27(9-10): 525–531.
  73. Crespi BJ. Oxytocin, testosterone, and human social cognition. Biol Rev Camb Philos Soc. 2016; 91(2): 390–408.
  74. Ding C, Magkos F. Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspectives. Curr Obes Rep. 2019; 8(3): 301–316.
  75. Leng G, Caquineau C, Sabatier N. Regulation of oxytocin secretion. Vitam Horm. 2005; 71: 27–58.
  76. Caligioni CS, Oliver C, Jamur MC, et al. Presence of oxytocin receptors in the gonadotrophin-releasing hormone (GnRH) neurones in female rats: a possible direct action of oxytocin on GnRH neurones. J Neuroendocrinol. 2007; 19(6): 439–448.
  77. Salehi MS, Khazali H, Mahmoudi F, et al. Oxytocin Intranasal Administration Affects Neural Networks Upstream of GNRH Neurons. J Mol Neurosci. 2017; 62(3-4): 356–362.
  78. Ivell R, Furuya K, Brackmann B, et al. Expression of the oxytocin and vasopressin genes in human and baboon gonadal tissues. Endocrinology. 1990; 127(6): 2990–2996.
  79. Argiolas A. Oxytocin stimulation of penile erection. Pharmacology, site, and mechanism of action. Ann N Y Acad Sci. 1992; 652: 194–203.
  80. Melis MR, Stancampiano R, Argiolas A, et al. Oxytocin-induced penile erection and yawning: site of action in the brain. Brain Res. 1986; 398(2): 259–265.
  81. Frayne J, Townsend D, Nicholson HD. Effects of oxytocin on sperm transport in the pubertal rat. J Reprod Fertil. 1996; 107(2): 299–306.
  82. Robinson DA, Wei F, Wang GD, et al. Oxytocin mediates stress-induced analgesia in adult mice. J Physiol. 2002; 540(Pt 2): 593–606.
  83. Jahromi BN, Dabbaghmanesh MH, Bakhshaie P, et al. Assessment of oxytocin level, glucose metabolism components and cutoff values for oxytocin and anti-mullerian hormone in infertile PCOS women. Taiwan J Obstet Gynecol. 2018; 57(4): 555–559.
  84. Gołyszny M. “Stare” i “nowe” neuropeptydy jako modulatory czynności osi stresu. Psychiatria. 2018; 2(5): 409–422.
  85. Schneiderman I, Kanat-Maymon Y, Zagoory-Sharon O, et al. Mutual influences between partners' hormones shape conflict dialog and relationship duration at the initiation of romantic love. Soc Neurosci. 2014; 9(4): 337–351.
  86. Bosch OJ, Dabrowska J, Modi ME, et al. Oxytocin in the nucleus accumbens shell reverses CRFR2-evoked passive stress-coping after partner loss in monogamous male prairie voles. Psychoneuroendocrinology. 2016; 64: 66–78.
  87. Lee HJ, Macbeth AH, Pagani JH, et al. Oxytocin: the great facilitator of life. Prog Neurobiol. 2009; 88(2): 127–151.
  88. Nagasawa M, Okabe S, Mogi K, et al. Oxytocin and mutual communication in mother-infant bonding. Front Hum Neurosci. 2012; 6: 31.
  89. Odent M, Odent M. New reasons and new ways to study birth physiology. Int J Gynaecol Obstet. 2001; 75 Suppl 1: S39–S45.
  90. Matthiesen AS, Ransjö-Arvidson AB, Nissen E, et al. Postpartum maternal oxytocin release by newborns: effects of infant hand massage and sucking. Birth. 2001; 28(1): 13–19.
  91. Gottschalk MG, Domschke K. Oxytocin and Anxiety Disorders. Curr Top Behav Neurosci. 2018; 35: 467–498.
  92. Windle RJ, Shanks N, Lightman SL, et al. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology. 1997; 138(7): 2829–2834.
  93. Ditzen B, Schaer M, Gabriel B, et al. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry. 2009; 65(9): 728–731.
  94. De Groot AN, Vree TB, Hekster YA, et al. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. J Pharm Pharmacol. 1995; 47(7): 571–575.
  95. Cegieła U, Folwarczna J, Janiec R, Janiec W, Kaczmarczyk-Sedlak IH, Nowińska BE. Kompendium farmakologii. Wydawnictwo Lekarskie PZWL, Warszawa 2017.
  96. Leake RD, Weitzman RE, Fisher DA. Pharmacokinetics of oxytocin in the human subject. Obstet Gynecol. 1980; 56(6): 701–704.
  97. Ruis H, Rolland R, Doesburg W, et al. Oxytocin enhances onset of lactation among mothers delivering prematurely. Br Med J (Clin Res Ed). 1981; 283(6287): 340–342.
  98. Gutkowska J, Jankowski M. Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol. 2012; 24(4): 599–608.
  99. Aldana-Valenzuela C, Prieto-Pantoja JA, Hernández-Acevedo A. [Oxytocin and syndrome of inappropriate secretion of antidiuretic neonatal hormone. Case report of early severe hyponatremia and literature review]. Ginecol Obstet Mex. 2010; 78(12): 692–696.
  100. Sweeney G, Holbrook AM, Levine M, et al. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. Curr Ther Res Clinl Experiment. 1990; 47(3): 528–540.
  101. Hofmann SG, Fang A, Brager DN, et al. RETRACTED: Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies. Psychiatry Res. 2015; 228(3): 708–714.
  102. Leng G, Ludwig M. Intranasal Oxytocin: Myths and Delusions. Biol Psychiatry. 2016; 79(3): 243–250.
  103. Evans SL, Dal Monte O, Noble P, et al. Intranasal oxytocin effects on social cognition: a critique. Brain Res. 2014; 1580: 69–77.
  104. Heinrichs M, Baumgartner T, Kirschbaum C, et al. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry. 2003; 54(12): 1389–1398.
  105. Baumgartner T, Heinrichs M, Vonlanthen A, et al. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron. 2008; 58(4): 639–650.
  106. Guastella AJ, Mitchell PB, Mathews F. Oxytocin enhances the encoding of positive social memories in humans. Biol Psychiatry. 2008; 64(3): 256–258.
  107. Petrovic P, Kalisch R, Singer T, et al. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci. 2008; 28(26): 6607–6615.
  108. Arletti R, Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci. 1987; 41(14): 1725–1730.
  109. Grund T, Goyon S, Li Y, et al. Neuropeptide S Activates Paraventricular Oxytocin Neurons to Induce Anxiolysis. J Neurosci. 2017; 37(50): 12214–12225.
  110. Waldherr M, Neumann ID. Centrally released oxytocin mediates mating-induced anxiolysis in male rats. Proc Natl Acad Sci U S A. 2007; 104(42): 16681–16684.
  111. Gołyszny M, Obuchowicz E. Are neuropeptides relevant for the mechanism of action of SSRIs? Neuropeptides. 2019; 75: 1–17.
  112. Uvnäs-Moberg K, Bjökstrand E, Hillegaart V, et al. Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacology (Berl). 1999; 142(1): 95–101.
  113. Olff M, Langeland W, Witteveen A, et al. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectr. 2010; 15(8): 522–530.
  114. Koch SBj, van Zuiden M, Nawijn L, et al. Intranasal Oxytocin Administration Dampens Amygdala Reactivity towards Emotional Faces in Male and Female PTSD Patients. Neuropsychopharmacology. 2016; 41(6): 1495–1504.
  115. van Zuiden M, Frijling JL, Nawijn L, et al. Intranasal Oxytocin to Prevent Posttraumatic Stress Disorder Symptoms: A Randomized Controlled Trial in Emergency Department Patients. Biol Psychiatry. 2017; 81(12): 1030–1040.
  116. Sack M, Spieler D, Wizelman L, et al. Intranasal oxytocin reduces provoked symptoms in female patients with posttraumatic stress disorder despite exerting sympathomimetic and positive chronotropic effects in a randomized controlled trial. BMC Med. 2017; 15(1): 40.
  117. Guastella AJ, Howard AL, Dadds MR, et al. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009; 34(6): 917–923.
  118. Labuschagne I, Phan KL, Wood A, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology. 2010; 35(12): 2403–2413.
  119. Ansseau M, Legros JJ, Mormont C, et al. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology. 1987; 12(3): 231–236.
  120. Boer Jd, Westenberg H. Oxytocin in obsessive compulsive disorder. Peptides. 1992; 13(6): 1083–1085.
  121. Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry. 1996; 40(6): 547–549.
  122. Marazziti D, Baroni S, Giannaccini G, et al. Plasma Oxytocin Levels in Untreated Adult Obsessive-Compulsive Disorder Patients. Neuropsychobiology. 2015; 72(2): 74–80.
  123. Bujanow W. Letter: Is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J. 1974; 19(3): 323.
  124. Souza RP, Ismail P, Meltzer HY, et al. Variants in the oxytocin gene and risk for schizophrenia. Schizophr Res. 2010; 121(1-3): 279–280.
  125. Shilling PD, Feifel D. Potential of Oxytocin in the Treatment of Schizophrenia. CNS Drugs. 2016; 30(3): 193–208.
  126. Averbeck BB, Bobin T, Evans S, et al. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med. 2012; 42(2): 259–266.
  127. Goldman MB, Gomes AM, Carter CS, et al. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (Berl). 2011; 216(1): 101–110.
  128. Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011; 132(1): 50–53.
  129. Modabbernia A, Rezaei F, Salehi B, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs. 2013; 27(1): 57–65.
  130. Clarici A, Pellizzoni S, Guaschino S, et al. Intranasal adminsitration of oxytocin in postnatal depression: implications for psychodynamic psychotherapy from a randomized double-blind pilot study. Front Psychol. 2015; 6: 426.
  131. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010; 67(7): 692–694.
  132. Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012; 3(1): 16.
  133. Hall SS, Lightbody AA, McCarthy BE, et al. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012; 37(4): 509–518.
  134. Skrundz M, Bolten M, Nast I, et al. Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology. 2011; 36(9): 1886–1893.
  135. Higuchi T, Kaba H. Neuromodulatory role of oxytocin in the control of maternal behavior. Neural control of reproduction: Physiology and behavior. New York: S. Karger AG; 1997.
  136. Pedersen CA, Vadlamudi SV, Boccia ML, et al. Maternal behavior deficits in nulliparous oxytocin knockout mice. Genes Brain Behav. 2006; 5(3): 274–281.
  137. Nelson EE, Panksepp J. Brain substrates of infant-mother attachment: contributions of opioids, oxytocin, and norepinephrine. Neurosci Biobehav Rev. 1998; 22(3): 437–452.
  138. Gordon I, Zagoory-Sharon O, Leckman JF, et al. Oxytocin and the development of parenting in humans. Biol Psychiatry. 2010; 68(4): 377–382.
  139. Da Costa AP, Guevara-Guzman RG, Ohkura S, et al. The role of oxytocin release in the paraventricular nucleus in the control of maternal behaviour in the sheep. J Neuroendocrinol. 1996; 8(3): 163–177.
  140. Pryce CR, Martin RD. Motherhood in Human and Non-human Primates, Biosocial Determinants. Basel: Karger; 1995.
  141. Debiec J. Peptides of love and fear: vasopressin and oxytocin modulate the integration of information in the amygdala. Bioessays. 2005; 27(9): 869–873.
  142. Uvnäs-Moberg K. Antistress pattern induced by oxytocin. News in Physiological Sciences. 1998; 13(1): 22-25.
  143. Brummelte S, Galea LAM. Postpartum depression: Etiology, treatment and consequences for maternal care. Horm Behav. 2016; 77: 153-166.
  144. Ehlert U, Patalla U, Kirschbaum C, et al. Postpartum blues: salivary cortisol and psychological factors. J Psychosom Res. 1990; 34(3): 319–325.
  145. Uvnäs-Moberg U. Oxytocin, das Hormon der Nähe: Gesundheit–Wohlbefinden-Beziehung. Berlin: Springer-Verlag; 2016.
  146. Cummiskey KC, Dawood MY. Induction of labor with pulsatile oxytocin. Am J Obstet Gynecol. 1990; 163(6 Pt 1): 1868–1874.
  147. Moura D, Canavarro MC, Figueiredo-Braga M. Oxytocin and depression in the perinatal period-a systematic review. Arch Womens Ment Health. 2016; 19(4): 561–570.
  148. Strathearn L. Maternal neglect: oxytocin, dopamine and the neurobiology of attachment. J Neuroendocrinol. 2011; 23(11): 1054–1065.
  149. Bell AF, Carter CS, Steer CD, et al. Interaction between oxytocin receptor DNA methylation and genotype is associated with risk of postpartum depression in women without depression in pregnancy. Front Genet. 2015; 6: 243.
  150. Kimmel M, Clive M, Gispen F, et al. Oxytocin receptor DNA methylation in postpartum depression. Psychoneuroendocrinology. 2016; 69: 150–160.
  151. Jonas W, Mileva-Seitz V, Girard AW, et al. MAVAN Research Team. Genetic variation in oxytocin rs2740210 and early adversity associated with postpartum depression and breastfeeding duration. Genes Brain Behav. 2013; 12(7): 681–694.
  152. Lara-Cinisomo S, McKenney K, Di Florio A, et al. Associations Between Postpartum Depression, Breastfeeding, and Oxytocin Levels in Latina Mothers. Breastfeed Med. 2017; 12(7): 436–442.
  153. Kroll-Desrosiers AR, Nephew BC, Babb JA, et al. Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year. Depress Anxiety. 2017; 34(2): 137–146.
  154. Figueiredo B, Canário C, Field T. Breastfeeding is negatively affected by prenatal depression and reduces postpartum depression. Psychol Med. 2014; 44(5): 927–936.
  155. Stuebe AM, Grewen K, Meltzer-Brody S. Association between maternal mood and oxytocin response to breastfeeding. J Womens Health (Larchmt). 2013; 22(4): 352–361.
  156. Wang T, Shi C, Li X, et al. Injection of oxytocin into paraventricular nucleus reverses depressive-like behaviors in the postpartum depression rat model. Behav Brain Res. 2018; 336: 236–243.
  157. Ji H, Su W, Zhou R, et al. Intranasal oxytocin administration improves depression-like behaviors in adult rats that experienced neonatal maternal deprivation. Behav Pharmacol. 2016; 27(8): 689–696.
  158. Mah BL, Van Ijzendoorn MH, Smith R, et al. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40: 267–272.
  159. Mah BL, Van Ijzendoorn MH, Out D, et al. The Effects of Intranasal Oxytocin Administration on Sensitive Caregiving in Mothers with Postnatal Depression. Child Psychiatry Hum Dev. 2017; 48(2): 308–315.
  160. Donadon MF, Martin-Santos R, L Osório F. Oxytocin effects on the cognition of women with postpartum depression: A randomized, placebo-controlled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2021; 111: 110098.
  161. De Cagna F, Fusar-Poli L, Damiani S, et al. The Role of Intranasal Oxytocin in Anxiety and Depressive Disorders: A Systematic Review of Randomized Controlled Trials. Clin Psychopharmacol Neurosci. 2019; 17(1): 1–11.
  162. Badr HA, Zauszniewski JA. Kangaroo care and postpartum depression: The role of oxytocin. Int J Nurs Sci. 2017; 4(2): 179–183.
  163. Uvnäs-Moberg K. The oxytocin factor: Tapping the hormone of calm, love, and healing. Cambridge: Da Capo Press; 2003.
  164. Thul TA, Corwin EJ, Carlson NS, et al. Oxytocin and postpartum depression: A systematic review. Psychoneuroendocrinology. 2020; 120: 104793.